证券代码：688176 证券简称：亚虹医药 公告编号：2025-030 江苏亚虹医药科技股份有限公司 关于 2022 年限制性股票激励计划首次授予部分第二个 归属期及预留授予部分第一个归属期归属结果暨股份 上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、本次限制性股票归属的决策程序及相关信息披露 （一）2022 年 7 月 27 日，公司召开第一届董事会第十二次会议，会议审议通 过了《关于公司<2022 年限制性股票激励计划（草案）>及其摘要的议案》《关于 公司<2022 年限制性股票激励计划实施考核管理办法>的议案》以及《关于提请股 东大会授权董事会办理 2022 年限制性股票激励计划相关事宜的议案》。公司独立 董事就本次激励计划相关议案发表了独立意见。 1 同日，公司召开第一届监事会第十次会议，审议通过了《关于公司<2022 年限 制性股票激励计划（草案）>及其摘要的议案》《关于公司<2022 年限制性股票激 励计划实施考核管理办法>的议案》以及《关于核实公司<2022 年限制性股票激励 ...

Meeting Overview - The shareholders' meeting of Jiangsu Yahon Pharmaceutical Technology Co., Ltd. was held on July 25, 2025, at Wanxin Hotel, Shanghai [1] - A total of 349 ordinary shareholders attended the meeting, representing 200,209,901 voting rights, which accounts for 35.6669% of the company's total voting rights [1] Voting Results - All non-cumulative voting proposals were approved, with significant support from ordinary shareholders [1] - For the first proposal, 197,451,292 votes (98.6221%) were in favor, while 1,417,972 votes (0.7082%) were against, and 1,340,637 votes (0.6697%) were abstained [1] - For the second proposal, 197,470,994 votes (98.6319%) were in favor, with 1,241,781 votes (0.6202%) against, and 1,497,126 votes (0.7479%) abstained [1] Legal Compliance - The meeting's convening, procedures, and voting were confirmed to comply with the Company Law of the People's Republic of China and the company's articles of association, ensuring the legality and validity of the voting results [2]

证券代码：688176 证券简称：亚虹医药 公告编号：2025-029 江苏亚虹医药科技股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 7 月 25 日 （二） 股东大会召开的地点：上海市浦东新区高科西路 551 号万信酒店一楼会 议室 （五） 公司董事、监事和董事会秘书的出席情况 1、 公司在任董事9人，出席9人； 2、 公司在任监事3人，出席3人； 3、 董事会秘书兼财务负责人出席了本次会议。 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 349 | | --- | --- | | 普通股股东人数 | 349 | | 2、出席会议的股东所持有的表决权数量 | 200,209,901 | | 普通股股东所持有表决权数量 | 200,209,901 | | 3、出席会议的 ...

北京市嘉源律师事务所 关于江苏亚虹医药科技股份有限公司 2025 年第一次临时股东大会的 法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国 · 北京 望师事务所 YUAN LAW OFFICES 北京 BEIJING · 上海 SHANGHAI · 深圳 SHENZHEN · 香港 HONG KONG · 广州 GUANGZHOU · 西安 XI'AN 致:江苏亚虹医药科技股份有限公司 北京市嘉源律师事务所 关于江苏亚虹医药科技股份有限公司 2025 年第一次临时股东大会的法律意见书 嘉源(2025)-04-550 北京市嘉源律师事务所(以下简称"本所")接受江苏亚虹医药科技股份有 限公司(以下简称"亚虹医药"或"公司")的委托,根据《中华人民共和国公 司法》(以下简称"《公司法》")《上市公司股东会规则》(以下简称"《股东 会规则》")等现行有效的法律、行政法规、部门规章、规范性文件(以下简称 "法律法规")以及《江苏亚虹医药科技股份有限公司章程》(以下简称"《公司 章程》"）的有关规定,指派本所律师对公司 2025年第一次临时股东大会(以 下简称"本次股东大会")进行见证,并依法出具本法律 ...

Core Points - The company is holding a shareholders' meeting to ensure the orderly conduct of the meeting and the rights of shareholders [1][2] - The meeting will include a voting process combining on-site and online methods, with results to be announced afterward [3][5] - The company plans to use remaining raised funds totaling RMB 87.04 million to permanently supplement working capital [11][13] Group 1: Meeting Procedures - Shareholders and their representatives must arrive 30 minutes early for registration and verification of attendance [1] - The meeting will have a structured agenda, allowing shareholders to speak only with the host's permission and within a time limit [2] - Voting will be conducted through both on-site and online methods, with results published in a subsequent announcement [3][5] Group 2: Fund Usage - The company intends to use RMB 87.04 million of the remaining raised funds for working capital, which includes interest income and investment returns [11][13] - The total amount of excess raised funds is RMB 310.73 million, with the proposed usage not exceeding 30% of this total [13][14] - The company assures that this fund usage will not affect the implementation of investment projects and complies with relevant regulations [14]

Core Insights - Yahui Pharmaceutical (688176) is accelerating the review process for its product APL-1702, a photodynamic therapy system for treating high-grade squamous intraepithelial lesions (HSIL), aiming for swift market approval [1] - The company reported a revenue of 202 million yuan in 2024, achieving its commercial operation breakeven target, and a 151.24% year-on-year revenue growth in Q1 2025 [2] - APL-2501, an antibody-drug conjugate for treating various advanced tumors, is progressing well, with plans to complete CMC and GLP toxicology studies in 2025 [2] - APL-2302, a novel oral small molecule inhibitor targeting USP1, has received approval for clinical trials in the US and China, with the first patient enrolled in March 2025 [3] Group 1 - APL-1702 is the first product to show positive results in international Phase III trials for HSIL, with a target population of approximately 2.1 million patients in China [1] - The company is conducting systematic research on market accessibility and payment assurance, and is advocating for policies to support cervical cancer prevention [1] Group 2 - The company has exceeded its initial revenue target for 2024, achieving 202 million yuan, and reported a significant increase in Q1 2025 revenue [2] - APL-2501 has shown superior characteristics compared to competitors, with plans for further development and clinical trial submissions in 2026 [2] Group 3 - APL-2302 is designed to induce synthetic lethality in tumors by inhibiting USP1, with ongoing clinical trials expected to advance in 2025 [3] - The company has received regulatory approvals for APL-2302 trials in both the US and China, indicating strong progress in its clinical development pipeline [3]

江苏亚虹医药科技股份有限公司 2025 年第一次临时股东大会 | 《关于使用剩余超募资金永久补充流动资金的议案》 9 | | --- | 江苏亚虹医药科技股份有限公司 2025 年第一次临时股东大会须知 会议资料 二〇二五年七月 1 为了保证股东在本次股东大会依法行使职权，确保股东大会的正常秩序和 议事效率，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》《江苏亚虹医药科技股份有限公司章程》（以下简称"《公 司章程》"）、《江苏亚虹医药科技股份有限公司股东大会议事规则》等有关规 定，江苏亚虹医药科技股份有限公司（以下简称"公司"或"亚虹医药"）特制 定本次股东大会会议须知： 一、为确认出席大会的股东及股东代理人或其他出席者的出席资格，会议 工作人员将对出席会议者的身份进行必要的核对工作，请被核对者给予配合。 二、为保证本次大会的严肃性和正常秩序，切实维护股东的合法权益，请 出席大会的股东或股东代理人或其他出席者提前 30 分钟到达会场签到确认参会 资格。在会议主持人宣布现场出席会议的股东和股东代理人人数及所持有的表 决权数量之前，会议登记应当终止。会议登记终止后进场的股东无权 ...

Core Viewpoint - On July 14, the Shanghai Composite Index rose by 0.27%, with institutional investors appearing on the trading lists of 35 stocks, net buying 19 and net selling 16 [1] Institutional Trading Summary - Institutional special seats net bought the most in Xiangyang Bearing, which closed at the daily limit with a turnover rate of 27.67% and a transaction amount of 2.076 billion yuan, net buying 110.74 million yuan [2] - San Chuan Wisdom closed up 15.27% with a turnover rate of 32.50%, net buying 75.27 million yuan, but had a net outflow of 35.2 million yuan [2] - Zhongke Magnetic Industry closed down 5.10% with a turnover rate of 45.77%, net buying 53.99 million yuan, but had a net outflow of 49.77 million yuan [2] Market Performance - The average increase of stocks with institutional net purchases was 2.36%, outperforming the Shanghai Composite Index [3] - Stocks like Changrong Co. and Xinling Electric showed strong performance, closing at the daily limit [3] - Historical data indicates a 52.06% probability of stocks with institutional net purchases rising the next day, and a 39.70% probability of rising in the following three days [3] Earnings Forecasts - Among the stocks with institutional net purchases, four have released half-year earnings forecasts, with Yuhua Development expected to have a net profit of 200 million yuan, a year-on-year increase of 708% [3] Net Selling Summary - The stock with the highest net selling by institutions was Siyuan Electric, with a net selling amount of 162.84 million yuan, while also seeing a net inflow of 98.77 million yuan [3] - Dazhihui was noted for a net selling of 120.24 million yuan, with a significant net outflow of 433 million yuan [4] Deep and Shanghai Stock Connect - On July 14, 15 stocks on the trading list had appearances from the Deep and Shanghai Stock Connect, with Siyuan Electric and Zhongke Jincai seeing net purchases of 139 million yuan and 113 million yuan respectively [7][8] - Stocks like Hengbao Co. and Greenland Holdings experienced significant net selling amounts of 193 million yuan and 79.38 million yuan respectively [8]

Market Overview - The Sci-Tech Innovation Board (STAR Market) index decreased by 0.21%, closing at 992.39 points, with a total trading volume of 2.875 billion shares and a turnover of 95.999 billion yuan, resulting in an average turnover rate of 1.61% [1] - Among the tradable stocks on the STAR Market, 358 stocks closed higher, with 6 stocks hitting the daily limit, while 219 stocks closed lower [1] Stock Performance - The highest turnover rate was recorded by Yitang Co., Ltd., a newly listed stock, which saw a decline of 1.86% and a turnover rate of 19.71%, with a daily transaction amount of 820 million yuan and a net outflow of 141 million yuan in main funds [1] - Other notable stocks with high turnover rates included Borui Data, which increased by 7.23% with a turnover rate of 18.73%, and Jin Chengzi, Zhongyan Co., and Saifen Technology, with turnover rates of 15.34%, 15.10%, and 14.80% respectively [1] High Turnover Stocks - Among stocks with a turnover rate exceeding 5%, 43 stocks increased in value today, with the highest gains from Zhijiang Biology (20.00%), Nanxin Pharmaceutical (18.16%), and Yanhong Pharmaceutical (17.32%) [2] - The pharmaceutical and biological sector had the most stocks with high turnover rates, totaling 20, followed by the computer and power equipment sectors with 10 and 6 stocks respectively [2] Fund Flow Analysis - In terms of fund flow, 32 stocks with high turnover rates experienced net inflows, with Zhijiang Biology, Yanhong Pharmaceutical, and Nanxin Pharmaceutical receiving the most significant net inflows of 100 million yuan, 82.6559 million yuan, and 31.76 million yuan respectively [2] - Conversely, Yitang Co., Ltd., Dingtong Technology, and Shijia Photon saw the largest net outflows, amounting to 141 million yuan, 89.163 million yuan, and 76.5522 million yuan respectively [2] Leverage Fund Movements - Recent data indicates that 37 stocks with high turnover rates received net purchases from leveraged funds, with Yitang Co., Ltd., Rongchang Biology, and Dingtong Technology seeing significant increases in financing balances of 260 million yuan, 80.9046 million yuan, and 79.4712 million yuan respectively [3] - Stocks with decreased financing balances included Youfang Technology, Yingshi Innovation, and Guangda Special Materials, with reductions of 142 million yuan, 82 million yuan, and 49.5677 million yuan respectively [3] Notable Stocks on July 14 - A list of notable stocks with high turnover rates includes: - Yitang Co., Ltd. (688729): Closing price 20.55, daily change -1.86%, turnover rate 19.71%, net outflow -140.50 million yuan [4] - Borui Data (688229): Closing price 64.55, daily change 7.23%, turnover rate 18.73%, net inflow 21.51 million yuan [4] - Jin Chengzi (688291): Closing price 35.28, daily change 1.50%, turnover rate 15.34%, net inflow 3.69 million yuan [4] - Zhongyan Co. (688716): Closing price 37.16, daily change 9.01%, turnover rate 15.10%, net inflow 24.58 million yuan [4] - Saifen Technology (688758): Closing price 17.54, daily change 3.91%, turnover rate 14.80%, net inflow 10.26 million yuan [4]

Group 1 - The Shanghai Stock Exchange has released the "Self-Regulatory Supervision Guidelines for Companies Listed on the Sci-Tech Innovation Board No. 5 - Sci-Tech Growth Tier" [1] - The reform does not impose additional listing thresholds for unprofitable companies entering the Sci-Tech Growth Tier, allowing 32 existing unprofitable companies to enter immediately upon the guideline's implementation [1] - Newly registered unprofitable companies will enter the Sci-Tech Growth Tier from the date of their listing [1] Group 2 - Investors participating in the subscription and trading of newly registered stocks in the Sci-Tech Growth Tier must sign a "Risk Disclosure Statement for the Sci-Tech Growth Tier" [2] - The 32 existing companies that have not yet removed the "U" designation include: Zejing Pharmaceutical, Junshi Biosciences, Frontier Biotech, Qingyun Technology, Hehui Optoelectronics, Jingjin Electric, BeiGene, Dize Pharmaceutical, Maiwei Biotech, Aojie Technology, Yuhong Pharmaceutical, Shouyao Holdings, Haichuang Pharmaceutical, CloudWalk Technology, Yifang Biotech, Obsidian Optics, Mengke Pharmaceutical, Nuo Cheng Jianhua, Xinke Mobile, Xinghuan Technology, Yutai Micro, Yuntian Lifa, Tianzhihang, Qi Anxin, Hanwujin, Yihua Tong, Aifute, Huizhiwei, Xinlian Integrated, Zhixiang Jintai, Shengke Communication, and Zhongjuxin [2]